Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
NEW YORK, Feb. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
Click here to learn about the case: http://docs.wongesq.com/TTPH-Info-Request-Form-1089. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TTPH-Info-Request-Form-1089.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
